Another CEPI partner, Clover Biopharmaceuticals, has become the latest vaccine developer to sign an advance purchase agreement with COVAX to make their COVID-19 vaccine available to populations worldwide.
Under the new agreement between Clover and our COVAX partner, Gavi, up to 414 million doses are set to be made available to participating countries in 2021 and 2022. CEPI’s significant early investments have been critical to the development of Clover’s vaccine candidate, and were directly linked to access commitments which enabled this deal.
Since late Spring, 2020, CEPI has provided up to $328 million to support preclinical and clinical testing of the candidate vaccine, in addition to scaling-up the biotech’s in-house manufacturing capacity. Clover yesterday announced that its pivotal global Phase 2/3 clinical trial—funded by CEPI—is now fully enrolled, and that interim efficacy data is expected in Q3.
COVAX has now distributed over 100 million vaccines since its launch in February this year. Supply of Clover’s vaccine is anticipated to start in the last quarter of the year, pending Emergency Use Licensure from the World Health Organization (WHO).
To learn more visit https://cepi.net/news_cepi/from-lab-to-potential-jab-clovers-covid-19-vaccine-story/
Read moreEDCTP invites submission of abstracts highlighting original contributions on strategic EDCTP research topics and on research capacity strengthening, linked to the Forum theme. Investigators involved in EDCTP-funded projects are encouraged to use this opportunity to share new developments and results from their projects. The deadline for abstracts is 28 June 2021.
Format and eligibility:
Abstracts must be submitted in English and should not exceed 300 words
Abstracts should follow the format: Background; Methods; Results; Conclusions
Abstracts must not have been published or submitted for presentation to any other national or international meeting.Submission: Abstracts must be submitted via the online system by 28 June 2021. Only abstracts submitted online by the deadline will be considered. Detailed instructions are available in the online submission system - https://edctpforum.eventsair.com/edctp-forum-2021/abstract-submission. For questions regarding abstracts, please contact the EDCTP Forum Team (forum@edctp.org).
Evaluation procedure:
All submitted abstracts will be reviewed by the Forum scientific programme committee and external experts, in collaboration with EDCTP secretariat members. Selection of abstracts will be based on the following criteria: Abstract quality; Relevance to the Forum theme and to EDCTP; Significance of the reported results
Applicants will be notified of the outcome of the review by 14 July 2021.
Please note that the final decision on whether the abstract is accepted and, if so, whether it will be for a poster or oral presentation will be made by EDCTP and the Forum Programme Committee.
Presenting authors whose abstracts have been accepted will receive further instructions for presenting their abstract. All presenters will be required to pre-record their presentations.
Vaccination plays an important role in the management of infectious diseases. Lessons from HIV on preparedness, hesitancy and ethics play a crucial role in preparing a population for vaccination. The arrival of the COVID-19 vaccines provides a fascinating example.
This webinar will explore some of the experiences of vaccine programmes for both HIV and COVID-19 and the ethical issues around vulnerability, equity of access, hesitancy and field experiences with vaccine initiatives. This is a highly topical issue with learnings from the HIV pandemic.
The programme presents four perspectives from world-leading experts with expertise in both HIV and COVID-19. We are privileged to have the current head of the International AIDS Society examine ethical issues and a wide range of perspectives from Prof. Gray (South Africa), Dr. Ward (France), Prof. Kamarulzaman (Malaysia) and Dr. Bonner (United States).
The 2nd webinar on "Vaccines and Vulnerabilities - HIV COVID and Back" is set to take place on Thursday, 1 July 2021 at 15:00 BST / 16:00 CEST. Complimentary registration is provided by AIDSImpact https://virology.eventsair.com/aidsim2021ws/registrationjuly/Site/Register